The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2023 | The efficacy of venetoclax-based salvage therapy in patients with previously treated R/R AML
Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses unmet needs in relapsed/refractory (R/R) acute myeloid leukemia (AML), and further explains the efficacy of venetoclax-based salvage regimens in patients with R/R AML previously treated with a FLT3 or IDH inhibitor. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
